Literature DB >> 22882743

Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades.

Mehrad Adibi1, Ramy Youssef, Shahrokh F Shariat, Yair Lotan, Christopher G Wood, Arthur I Sagalowsky, Richard Zigeuner, Francesco Montorsi, Christian Bolenz, Vitaly Margulis.   

Abstract

OBJECTIVE: To evaluate temporal trends in clinicopathological features and oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
METHODS: Utilizing a multi-institutional database of patients treated with radical nephroureterectomy between 1983 and 2007, we compared clinicopathological features and survival outcomes over the past three decades using the following cohorts: group 1 comprised of patients treated before the 1990s (n = 106), group 2 from 1990 to1999 (n = 655), and group 3 from 2000 to 2007 (n = 701). Survival rates were compared using Kaplan-Meier survival analysis.
RESULTS: The study included 1462 patients, 992 men and 470 women, with 36 months median follow up (range 1-250 months) after radical nephroureterectomy. Tumors were organ confined (≤T2/N0) in 88% and high-grade in 64%. Neoadjuvant and adjuvant systemic chemotherapy was administered in 47 (3.2%) and 171 (11.7%) patients, respectively. There was a significant increase in the use of laparoscopic radical nephroureterectomy, endoscopic management of urothelial carcinoma and utilization of perioperative chemotherapy between decades 1 to 3. There were no significant differences in pathological stage distribution. The overall 5-year disease-free survival rates were 66 ± 5%, 68.5 ± 2% and 71 ± 2%, and the 5-year cancer-specific survival rates were 75 ± 5%, 72 ± 2%, and 75 ± 2% for groups 1, 2 and 3, respectively, with no significant statistical differences between the three decades (P > 0.05).
CONCLUSION: Outcomes after radical nephroureterectomy have not changed significantly over the past three decades, despite staging and surgical refinements. Utilization of perioperative systemic chemotherapy in urothelial carcinoma management remains low. Further improvements in outcomes of urothelial carcinoma patients necessitate rigorous investigation of multimodal treatment approaches.
© 2012 The Japanese Urological Association.

Entities:  

Mesh:

Year:  2012        PMID: 22882743     DOI: 10.1111/j.1442-2042.2012.03110.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  15 in total

1.  Synchronous Bilateral Carcinoma of the Ureters. Report of a Case and a Short Discussion of the Literature.

Authors:  Dimitrios Sidiropoulos; Filippos Kapogiannis; Panagiota Kripouri; Dimitrios Filippou; Konstantinos Vlassis
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  [Surgical management for upper urinary tract transitional cell carcinoma].

Authors:  S Schmidt; A Spek
Journal:  Urologe A       Date:  2015-08       Impact factor: 0.639

3.  Robot-assisted nephroureterectomy for upper tract urothelial carcinoma: results from three high-volume robotic surgery institutions.

Authors:  Ruben De Groote; Karel Decaestecker; Alessandro Larcher; Sarah Buelens; Elise De Bleser; Frederiek D'Hondt; Peter Schatteman; Nicolaas Lumen; Francesco Montorsi; Alexandreμ Mottrie; Geert De Naeyer
Journal:  J Robot Surg       Date:  2019-04-30

4.  TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma.

Authors:  Ramy F Youssef; Laura-Maria Krabbe; Shahrokh F Shariat; Yair Lotan; Arthur I Sagalowsky; Jay Raman; Christopher G Wood; Alon Weizer; Marco Roscigno; Francesco Montorsi; Christian Bolenz; Mesut Remzi; Karim Bensalah; Wassim Kassouf; Vitaly Margulis
Journal:  World J Urol       Date:  2015-05-10       Impact factor: 4.226

Review 5.  The role of systemic chemotherapy in management of upper tract urothelial cancer.

Authors:  Bishoy A Gayed; Gregory R Thoreson; Vitaly Margulis
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

6.  Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Aditya Bagrodia; Samuel Kaffenberger; Andrew Winer; Katie Murray; Michael Vacchio; Junting Zheng; Irina Ostrovnaya; Bernard H Bochner; Guido Dalbagni; Eugene K Cha; Jonathan A Coleman
Journal:  World J Urol       Date:  2018-01-17       Impact factor: 4.226

7.  Visceral to total obesity ratio and severe hydronephrosis are independently associated with prolonged pneumoperitoneum operative time in patients undergoing laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Keisuke Shigeta; Eiji Kikuchi; Masayuki Hagiwara; Seiya Hattori; Gou Kaneko; Masanori Hasegawa; Toshikazu Takeda; Masahiro Jinzaki; Hirotaka Akita; Akira Miyajima; Ken Nakagawa; Mototsugu Oya
Journal:  Springerplus       Date:  2015-06-24

8.  Prognostic factors and outcomes of primary transitional cell carcinoma of the ureter: a population-based study.

Authors:  Tao Ding; Zhuojun Zheng; Renfang Xu; Cuixing Zhou
Journal:  Oncotarget       Date:  2017-07-27

9.  Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial.

Authors:  T van Doeveren; P J van Leeuwen; K K H Aben; M van der Aa; M Barendrecht; E R Boevé; E B Cornel; A G van der Heijden; K Hendricksen; W Hirdes; A Kooistra; B Kroon; A M Leliveld; R P Meijer; H van Melick; B Merks; T M de Reijke; P de Vries; L F A Wymenga; B Wijsman; J L Boormans
Journal:  Contemp Clin Trials Commun       Date:  2018-02-28

10.  Role of Microtubule-Associated Protein 1b in Urothelial Carcinoma: Overexpression Predicts Poor Prognosis.

Authors:  Tsu-Ming Chien; Ti-Chun Chan; Steven Kuan-Hua Huang; Bi-Wen Yeh; Wei-Ming Li; Chun-Nung Huang; Ching-Chia Li; Wen-Jeng Wu; Chien-Feng Li
Journal:  Cancers (Basel)       Date:  2020-03-09       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.